Skip to main content.

Clinical Trials

The following clinical trials are currently recruiting participants. If you would like more information regarding the trial or how to participate, please contact the study coordinator.

Trial Name Sponsor Summary Details Study Coordinator
Staged- PKD Sanofi Placebo-controlled study to determine the effect of venglustat on the rate of total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD).
  • Time commitment: 13 visits ranging from 2 - 4 hours
  • Procedures: Blood and urine labs, 4 MRI's, ECG, eye exams and physical exams
  • Eligibility: Age 18 to 50 GFR 45 to 90, NOT taking tolvaptan/Jynarque

Cathy Creed

DUPLEX Retrophin Study of an investigational medication (Sparsentan) in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
This study will be blinded and patients will be randomly assigned to take either Sparsentan or Irbesartan, to see which treatment has a better effect on declining kidney function and the level of protein in the urine.
  • Length: 2 years
  • Time: Approximately 2 hours per visit
  • Procedures: blood and urine labs, ECG, physical exam questionnaires
  • Eligibility: age 18 to 75, GFR 30 and above, diagnosed with FSGS

Cathy Creed

Cognitive Impairment KUMC Kidney Institute Evaluation of the changes in memory and thinking before and after transplant in relation to changes seen in images of the brain
  • Length: 1-2 years
  • Time commitment: 1-2 visits pre-transplant, and 2 visits prost-transplant to complete assessments
  • Procedures: Memory assessments, brain MRI, collection of blood and urine, medical history, and questionnaires
  • Eligibility: age 25-70, pre-transplant ESRD patients listed for renal transplantation at KU

Sean Obrien
Jessica Wilson

PKD Biomarker Repository NIH Identification of reliable biological markers of cyst growth in early stages of PKD
  • Length: 5 years
  • Time commitment:  Two hours once per year Procedures: MRI, blood and urine labs, and questionnaires
  • Eligibility: age 4-35, with early stage PKD, normal kidney function, family history of PKD, individuals without PKD diagnosis may also participate
Cathy Creed
Elisabeth Laundy

PKD Registry NIH Collect and store medical information in a PKD database used by investigators of KUMC to assess feasibility when developing new PKD studies and to recruit for future trials.
  • Length: Indefinitely
  • Time commitment: 30 min. visit (may be over the phone
  • Procedures: Questionnaire
  • Eligibility: Diagnosed with PKD
Elisabeth Laundy
Cathy Creed
Debbie Griffin
CRISP IV University of Pittsburgh
NIH
NIDDK
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) IV: Prognosis for End-Stage Renal Disease and Biomarker Validation 
  • Length: 4 years
  • Time commitment: One in-person enrollment visit - 1 hour
  • Two blood draws - 30-minute visit to a lab
  • Three times a year - 30-minute telephone visit
  • Procedures: Blood labs, medical history and questionnaires
  • Eligibility: Participated in the past CRISP studies and have not reached end stage renal disease (ESRD)or participated in the HALT-PKD study
Elisabeth Laundy
Debbie Griffin
Fabry Registry Genzyme Collection of clinical data on patients with Fabry disease around the world in an effort to help health professionals involved in treatment or diagnosis better understand Fabry Disease and its management
  • Length: Indefinitely
  • Time commitment: Data will be obtained from medical record. 30 minutes or less phone call if additional information needed
  • Procedures: Questionnaires
  • Eligibility: Diagnosed with Fabry Disease
Debbie Griffin
Renal Tubular Function in Living Donors Investigator initiated Evaluate the renal tubular function pre- and post-nephrectomy in living donors.
  • The study will help to better understand the long-term effects of loss of nephrons on tubular function and injury in otherwise healthy humans. This will be a prospective trial where living donors will have renal function and tubular function checked before nephrectomy and at one year post-nephrectomy.
Sean Obrien
Jessica Wilson
Cognitive Function-Everolimus Novartis, llT Title: Alterations in Cognitive Function and Cerebral Blood Flow after Conversion from Calcineurin Inhibitors to Everolimus. This single center longitudinal 12 weeks observational study will determine whether conversion from calcineurin inhibitor (Tacrolimus) to an mTOR inhibitor, Everolimus, is associated with improvement in cognition and cerebral blood flow. 
  • Goal: Enroll 20 kidney transplant recipients who will undergo conversion and 10 matched controls at the University of Kansas Medical Center.
Sean Obrien
Jessica Wilson

Study Coordinator Contact Information

Cathy Creed, RN
ccreed@kumc.edu
(913) 588-0053

Sean Obrien
sobrien5@kumc.edu
(913) 574-0895

Jessica Wilson
jwilson12@kumc.edu
(913) 574-0894

Debbie Griffin, RN, CDE
dgriffin3@kumc.edu
(913) 588-7691

Elisabeth Laundy
elaundy@kumc.edu
(913) 588-8983

KU School of Medicine

University of Kansas Medical Center
The Jared Grantham Kidney Institute
Mail Stop 3018
3901 Rainbow Boulevard
Kansas City, KS 66160